The Co-CEOs of the company, Michael Frankel and Howard Schwimmer, expressed their commitment to driving long-term shareholder value and stated their focus on executing value creation strategies for the benefit of their shareholders.
$アークベスト(ARCB.US)$initiated at buy by Jefferies, announced target price at $110.00. $サイア(SAIA.US)$initiated at buy by Jefferies, announced targe price at $350.00. $オートゾーン(AZO.US)$was upgraded by Evercore ISI Group from in-line to outperform, increased target price to $2700.00. $オラクル(ORCL.US)$was upgraded by Wolfe Research from peer perform to outperform, increased target price to $130.00. $ビル・ホールディングス(BILL.US)$was downg...
レックスフォード・インダストリアル・リアルティに関するコメント
コラムUS Top Rating Updates on 6/12: AZO, ORCL, BILL, KMX and More
$サイア(SAIA.US)$ initiated at buy by Jefferies, announced targe price at $350.00.
$オートゾーン(AZO.US)$ was upgraded by Evercore ISI Group from in-line to outperform, increased target price to $2700.00.
$オラクル(ORCL.US)$ was upgraded by Wolfe Research from peer perform to outperform, increased target price to $130.00.
$ビル・ホールディングス(BILL.US)$ was downg...
コラムTop upgrades and downgrades on 6/21: XOM, ADBE, UAA, BEKE and more
• $ABMインダストリーズ(ABM.US)$ : Baird Upgrades to Outperform from Neutral - PT $50
• $アメリカン・タワー(AMT.US)$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $チャーチ・アンド・ドワイト(CHD.US)$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $チューイー(CHWY.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $センティーン(CNC.US)$ : Credit Suisse Upgrades to Outperform from...
コラムToday's pre-market stock movers: ARRY, RIOT, MRNA, NVAX and more
• $アレイ・テクノロジーズ(ARRY.US)$ +12.87% (also names new CEO)
• $ツフィン・ソフトウェア・テクノロジーズ(TUFN.US)$ +43.41% (enters into definitive agreement to be acquired by Turn/River Capital in a $570 million transaction; TUFN shareholders will receive $13.00/share in cash)
• $シティアス・ファーマシューティカルズ(CTXR.US)$ +10.87% (reported topline results from the pivotal Phase 3 trial of I/ONTAK)
• $バイオエクセル・セラピューティクス(BTAI.US)$ +19.22% (FDA ha...
まだコメントはありません